keyword
MENU ▼
Read by QxMD icon Read
search

Panitumumab

keyword
https://www.readbyqxmd.com/read/28932126/dermopathy-associated-with-cetuximab-and-panitumumab-investigation-of-the-usefulness-of-moisturizers-in-its-management
#1
Shoichi Watanabe, Motoki Nakamura, Hiroki Takahashi, Masayasu Hara, Kei Ijichi, Daisuke Kawakita, Akimichi Morita
AIMS: Limited data regarding the objective evaluation of skin exsiccation caused by epidermal growth factor receptor (EGFR) inhibitors exist. Objective indices were applied to evaluate the usefulness of a moisturizer against skin exsiccation associated with the use of EGFR inhibitors in cancer patients. PATIENTS AND METHODS: Patients with either colorectal or head and neck cancer treated with either cetuximab or panitumumab were randomly assigned 1:2 to the prophylactic-treatment arm, where participants received prophylactical moisturizer treatment (heparinoid preparation, Hirudoid(®)), or to the symptomatic-treatment arm, where moisturizer was applied after the onset of cutaneous symptoms...
2017: Clinical, Cosmetic and Investigational Dermatology
https://www.readbyqxmd.com/read/28913158/dosimetry-and-first-human-experience-with-89-zr-panitumumab
#2
Liza Lindenberg, Stephen Adler, Ismail B Turkbey, Francesca Mertan, Anita Ton, Khanh Do, Shivaani Kummar, Esther Mena Gonzalez, Sibaprasad Bhattacharyya, Paula M Jacobs, Peter Choyke
(89)Zr-panitumumab is a novel immuno-PET radiotracer. A fully humanized IgG2 antibody, panitumumab binds with high affinity to the extracellular ligand binding domain of EGFR. Immuno-PET with radiolabeled panitumumab is a non-invasive method that could characterize EGFR expression in tumors and metastatic lesions. It might also assist in selecting patients likely to benefit from targeted therapy as well as monitor response and drug biodistribution for dosing guidance. Our objective was to calculate the maximum dosing for effective imaging with minimal radiation exposure in a small subset...
2017: American Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28870789/panitumumab-in-combination-with-preoperative-radiation-therapy-in-patients-with-locally-advanced-ras-wild-type-rectal-cancer-results-of-the-multicenter-explorative-single-arm-phase-2-study-neorit
#3
Kirsten Merx, Uwe M Martens, Melanie Kripp, Thomas Hoehler, Michael Geissler, Timo Gaiser, Sabine Mai, Peter Kienle, Sebastian Belle, Christoph Plöger, Udo Hieber, Frederik Wenz, Stefan Post, Ralf D Hofheinz
PURPOSE: Studies investigating combinations of anti-epidermal growth factor receptor monoclonal antibodies such as panitumumab or cetuximab with standard chemoradiation therapy protocols in rectal cancer have yielded disappointing results. Because of the supposed negative interaction of epidermal growth factor receptor inhibition and chemoradiation therapy, we conducted a phase 2 study using single-agent panitumumab in combination with radiation therapy in patients with RAS wild-type locally advanced rectal cancer...
June 28, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28853050/clinical-pharmacokinetics-and-pharmacodynamics-of-the-epidermal-growth-factor-receptor-inhibitor-panitumumab-in-the-treatment-of-colorectal-cancer
#4
REVIEW
Sander Ketzer, Kirsten Schimmel, Miriam Koopman, Henk-Jan Guchelaar
Despite progress in the treatment of metastatic colorectal cancer (mCRC) in the last 15 years, it is still a condition with a relatively low 5-year survival rate. Panitumumab, a fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFR), is able to prolong survival in patients with mCRC. Panitumumab is used in different lines of therapy in combination with chemotherapy, and as monotherapy for the treatment of wild-type (WT) RAS mCRC. It is administered as an intravenous infusion of 6 mg/kg every 2 weeks and has a t ½ of approximately 7...
August 29, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28844343/inclusion-of-elderly-or-frail-patients-in-randomized-controlled-trials-of-targeted-therapies-for-the-treatment-of-metastatic-colorectal-cancer-a-systematic-review
#5
REVIEW
Amandine Gouverneur, Francesco Salvo, Driss Berdaï, Nicholas Moore, Annie Fourrier-Réglat, Pernelle Noize
Treatment of metastatic colorectal cancer (mCRC) has been modified since the launching of targeted therapies. Colorectal cancer (CRC) is common in elderly patients; their representation in randomized controlled trials (RCTs) is thus crucial. This study aimed to evaluate and quantify the inclusion of elderly/frail patients in RCTs of targeted therapies in mCRC. A systematic review using Medline, Scopus, Cochrane Database and ISI Web of Science was performed to identify all phase II/III RCTs of bevacizumab, cetuximab, panitumumab, regorafenib and aflibercept in mCRC until January 2015...
August 22, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28811946/are-all-mutations-the-same-a-rare-case-report-of-coexisting-mutually-exclusive-kras-and-braf-mutations-in-a-patient-with-metastatic-colon-adenocarcinoma
#6
Anusha Vittal, Akshay Middinti, Anup Kasi Loknath Kumar
29-year-old Hispanic woman presented to the clinic with complaints of abdominal pain, nausea, fatigue, and constipation. Laboratory tests indicated the presence of iron deficiency anemia and transaminitis. Imaging evaluation revealed marked hepatomegaly with multiple hepatic metastases and pelvic lymphadenopathy. Biopsy of the hepatic lesions showed adenocarcinoma positive for pan-cytokeratin, CMA5.2, villin, and CDX2. She was positive for tumor markers CA 19-9, CA-125, and CEA. Upon further evaluation, she was found to have colorectal cancer positive for KRAS and BRAF mutations...
2017: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/28762849/first-line-carboplatin-pemetrexed-and-panitumumab-in-patients-with-advanced-non-squamous-kras-wild-type-wt-non-small-cell-lung-cancer-nsclc
#7
David R Spigel, Tarek M Mekhail, David Waterhouse, Terence Hadley, Charles Webb, Howard A Burris, John D Hainsworth, F Anthony Greco
BACKGROUND: We added panitumumab to standard combination chemotherapy as first-line treatment for patients with advanced KRAS WT non-squamous NSCLC. METHODS: Patients received panitumumab 9 mg/kg IV, pemetrexed 500 mg/m(2) IV, and carboplatin AUC = 6 IV every 21 days. After 6 cycles, maintenance therapy with panitumumab and pemetrexed was administered every 21 days until progressive disease or unacceptable toxicity. RESULTS: 29 of 66 patients (44%) had objective responses...
August 1, 2017: Cancer Investigation
https://www.readbyqxmd.com/read/28752777/anti-egfr-monoclonal-antibody-panitumumab-for-the-treatment-of-patients-with-metastatic-colorectal-cancer-an-overview-of-current-practice-and-future-perspectives
#8
Francesca Battaglin, Vincenzo Dadduzio, Francesca Bergamo, Chiara Manai, Marta Schirripa, Sara Lonardi, Vittorina Zagonel, Fotios Loupakis
Targeted agents alone or in combination with chemotherapy are current standard of treatment for metastatic colorectal cancer (mCRC). Panitumumab is a fully human monoclonal antibody which inhibits the epidermal growth factor receptor (EGFR). It is currently approved in combination with chemotherapy in first- and second-line and as a monotherapy in chemorefractory patients. RAS gene mutations confer resistance to anti-EGFR agents; thus, panitumumab is restricted to the treatment of RAS wild-type (WT) tumors...
July 28, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28750125/demonstrating-noninferiority-of-accelerated-radiotherapy-with-panitumumab-vs-standard-radiotherapy-with-cisplatin-in-locoregionally-advanced-squamous-cell-head-and-neck-carcinoma
#9
https://www.readbyqxmd.com/read/28750114/demonstrating-noninferiority-of-accelerated-radiotherapy-with-panitumumab-vs-standard-radiotherapy-with-cisplatin-in-locoregionally-advanced-squamous-cell-head-and-neck-carcinoma-reply
#10
Bingshu E Chen, Lillian L Siu, Wendy R Parulekar
No abstract text is available yet for this article.
July 27, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28736637/primary-and-acquired-resistance-to-biologic-therapies-in-gastrointestinal-cancers
#11
REVIEW
Sam J Lubner, Nataliya V Uboha, Dustin A Deming
Improvements in the understanding of cancer biology have led to therapeutic advances in the treatment of gastrointestinal cancers. Drugs which target the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways have led the way in colon cancer. Monoclonal antibodies (mAbs) such as bevacizumab, ramucirumab, cetuximab, and panitumumab, have improved progression free survival and overall survival (OS) for colorectal cancers and were quickly adopted. Human epidermal growth factor receptor 2 (HER2) has demonstrated significant benefit for gastroesophageal cancers and in the setting of HER2 amplification, trastuzumab in combination with chemotherapy has become the standard of care...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28712098/precision-medicine-in-metastatic-colorectal-cancer-relevant-carcinogenic-pathways-and-targets-part-1-biologic-therapies-targeting-the-epidermal-growth-factor-receptor-and-vascular-endothelial-growth-factor
#12
REVIEW
Benjamin A Weinberg, Marion L Hartley, Mohamed E Salem
The survival of patients with metastatic colorectal cancer has improved dramatically in recent years, with overall survival exceeding 3 years in large randomized clinical trials. There are now several treatment options for patients with metastatic colorectal cancer. In addition to chemotherapy backbones utilizing fluoropyrimidine, oxaliplatin, and irinotecan combinations, biologic agents that target specific oncogenic pathways have contributed to the improved survival observed in this patient population. This class of medications includes epidermal growth factor receptor (EGFR)-targeted drugs (cetuximab and panitumumab) and vascular endothelial growth factor (VEGF)-targeted therapies (bevacizumab, ramucirumab, ziv-aflibercept, and regorafenib)...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28708307/evaluation-of-short-term-effectiveness-of-eight-targeted-agents-combined-with-chemotherapy-for-treating-esophageal-gastric-junction-adenocarcinoma-a-network-meta-analysis
#13
Yong-Ming He, Chen Yu, Wei-Bing Li, Zhi-Peng Li, Nan Xu
This study aimed to evaluate the short-term effectiveness of eight targeted agents (ramucirumab, bevacizumab, rilotumumab, panitumumab, cetuximab, trebananib, trastuzumab, matuzumab) plus chemotherapy in esophageal-gastric junction adenocarcinoma (EGJA) by a network meta-analysis (NMA). PubMed, Embase, and Cochrane Library databases were systematically retrieved for randomized clinical trials (RCTs) concerning targeted agents plus chemotherapy in the treatment of EGJA. This NMA combined both direct and indirect evidence to evaluate odds ratio (OR) and to draw the surface under the cumulative ranking curve (SUCRA)...
July 14, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/28708103/pharmacogenomics-of-targeted-agents-for-personalization-of-colorectal-cancer-treatment
#14
REVIEW
Alessia Bignucolo, Elena De Mattia, Erika Cecchin, Rossana Roncato, Giuseppe Toffoli
The use of targeted agents in the treatment of metastatic colorectal cancer (CRC) has improved patient outcomes. Anti-epidermal growth factor receptor (anti-EGFR) agents (cetuximab and panitumumab) and antiangiogenic molecules (bevacizumab, regorafeninb, ramucirumab, and aflibercept) have been successfully integrated into clinical practice. Other drugs have been designed to target additional deregulated pathways in CRC, such as MAPK (mitogen-activated protein kinase)/PI3K-AKT (phosphatidylinositol-3-kinase-AKT serine/threonine kinase)/mTOR (mammalian target of rapamycin), HER-2 and 3 ( human epidermal growth factor receptor-2 and -3), and BRAF...
July 14, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28682222/the-clinical-effectiveness-and-cost-effectiveness-of-cetuximab-review-of-technology-appraisal-no-176-and-panitumumab-partial-review-of-technology-appraisal-no-240-for-previously-untreated-metastatic-colorectal-cancer-a-systematic-review-and-economic-evaluation
#15
Nicola Huxley, Louise Crathorne, Jo Varley-Campbell, Irina Tikhonova, Tristan Snowsill, Simon Briscoe, Jaime Peters, Mary Bond, Mark Napier, Martin Hoyle
BACKGROUND: Colorectal cancer is the fourth most commonly diagnosed cancer in the UK after breast, lung and prostate cancer. People with metastatic disease who are sufficiently fit are usually treated with active chemotherapy as first- or second-line therapy. Targeted agents are available, including the antiepidermal growth factor receptor (EGFR) agents cetuximab (Erbitux(®), Merck Serono UK Ltd, Feltham, UK) and panitumumab (Vecitibix(®), Amgen UK Ltd, Cambridge, UK). OBJECTIVE: To investigate the clinical effectiveness and cost-effectiveness of panitumumab in combination with chemotherapy and cetuximab in combination with chemotherapy for rat sarcoma (RAS) wild-type (WT) patients for the first-line treatment of metastatic colorectal cancer...
June 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28674212/therapeutic-efficacy-of-sym004-a-mixture-of-two-anti-egfr-antibodies-in-human-colorectal-cancer-with-acquired-resistance-to-cetuximab-and-met-activation
#16
Stefania Napolitano, Giulia Martini, Erika Martinelli, Valentina Belli, Alessia Parascandolo, Mikko O Laukkanen, Vincenzo Sforza, Floriana Morgillo, Davide Ciardiello, Fortunato Ciardiello, Teresa Troiani
PURPOSE: Cetuximab and panitumumab have an effective therapeutic response in a subset of RAS Wild-Type (WT) metastatic colorectal cancers (mCRCs). Despite molecular-driven selection, all patients do not respond to epidermal growth factor receptor (EGFR) inhibitors and the onset of secondary resistance limits their clinical benefit. EXPERIMENTAL DESIGN: We tested, in vitro and in vivo, the effect of SYM004, a 1:1 mixture of two recombinant human-mouse chimeric monoclonal antibodies (mAbs) directed against non-overlapping epitopes of the EGFR, on CRC models with acquired resistance to cetuximab...
June 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28665451/discordance-in-ras-mutations-between-primary-colon-tumor-and-metastases-a-real-event-or-a-matter-of-methodology
#17
Alfonso De Stefano, Mario Rosanova, Umberto Malapelle, Maurizio Martini, Stefano De Falco, Laura Attademo, Giovanni Fiore, Tonia Cenci, Claudio Bellevicine, Sabino De Placido, Giancarlo Troncone, Chiara Carlomagno
BACKGROUND: Analysis of K- and N-RAS mutations is mandatory before planning treatment of metastatic colorectal cancer, because only RAS wild-type (WT) patients can benefit from treatment with anti-EGFR monoclonal antibodies (cetuximab and panitumumab). CASE REPORT: Here we report the case of a 69-year-old male patient affected by metastatic sigmoid cancer. He underwent left hemicolectomy, and histology diagnosed a well-differentiated, pT4, node-positive adenocarcinoma; KRAS analysis performed with direct sequencing identified a mutation in exon 2 of the KRAS gene (GGT->GTT)...
June 20, 2017: International Journal of Biological Markers
https://www.readbyqxmd.com/read/28633089/first-line-panitumumab-plus-folfox4-or-folfiri-in-colorectal-cancer-with-multiple-or-unresectable-liver-metastases-a-randomised-phase-ii-trial-planet-ttd
#18
RANDOMIZED CONTROLLED TRIAL
Alfredo Carrato, Albert Abad, Bartomeu Massuti, Cristina Grávalos, Pilar Escudero, Federico Longo-Muñoz, José-Luis Manzano, Auxiliadora Gómez, María José Safont, Javier Gallego, Beatriz García-Paredes, Carles Pericay, Rosario Dueñas, Fernando Rivera, Ferrán Losa, Manuel Valladares-Ayerbes, Encarnación González, Enrique Aranda
BACKGROUND: In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]. However no trial has directly compared these combinations. METHODS: Multicentre, open-label study in untreated patients ≥ 18 years with (WT)-KRAS mCRC and multiple or unresectable liver-limited disease (LLD) randomised to either Pmab-FOLFOX4 or Pmab-FOLFIRI...
August 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28629896/randomized-phase-ii-study-of-preoperative-chemoradiotherapy-%C3%A2-panitumumab-followed-by-consolidation-chemotherapy-in-potentially-operable-locally-advanced-stage-iiia-n2-non-small-cell-lung-cancer-nrg-oncology-rtog-0839
#19
Martin J Edelman, Chen Hu, Quynh-Thu Le, Jessica S Donington, Warren D D'Souza, Adam P Dicker, Billy W Loo, Elizabeth M Gore, Gregory M M Videtic, Nathaniel R Evans, Joseph W Leach, Maximilian Diehn, Steven J Feigenberg, Yuhchyau Chen, Rebecca Paulus, Jeffrey D Bradley
INTRODUCTION: Multimodality therapy has curative potential in locally advanced NSCLC. Mediastinal nodal sterilization (MNS) after induction chemoradiotherapy (CRT) can serve as an intermediate marker for efficacy. NRG Oncology Radiation Therapy Oncology Group (RTOG) 0229 demonstrated the feasibility and efficacy of combining full-dose radiation (61.2 Gy) with chemotherapy followed by resection and chemotherapy. On the basis of that experience and evidence that EGFR antibodies are radiosensitizing, we explored adding panitumumab to CRT followed by resection and consolidation chemotherapy in locally advanced NSCLC with a primary end point of MNS...
September 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28622036/molecular-targeted-drugs-and-treatment-of-colorectal-cancer-recent-progress-and-future-perspectives
#20
Fang Geng, Zheng Wang, Hang Yin, Junxian Yu, Bangwei Cao
Nowadays, colorectal cancer is the fourth most common type of tumor all over the world. When diagnosed, ∼50%-60% of tumors have metastasized, thus resulting in a grim prognosis. Chemotherapy is regarded as standard treatment for patients with colorectal cancer, however, limitations of chemotherapy cannot be ignored, such as low selectivity, insufficient concentrations in tumor tissues, and systemic toxicity. Recently, six targeted drugs have been approved by the U.S. Food and Drug Administration (FDA) for treatment of metastatic colorectal cancer (mCRC), including bevacizumab, aflibercept, regorafenib, cetuximab, and panitumumab...
June 2017: Cancer Biotherapy & Radiopharmaceuticals
keyword
keyword
16315
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"